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Mechanisms of toxicity and cellular transport of anticancer metallodrugs, including platinum-based agents, have not yet 
been fully elucidated. Here, we studied the toxic effects and accumulation mechanisms of cisplatin in healthy rat kidneys ex 
vivo, using the Precision Cut Tissue Slices (PCTS) method. In addition, for the first time, we investigated the nephrotoxic 
effects of an experimental anticancer cyclometallated complex [Au(pyb-H)(PTA)Cl]PF6 (PTA = 1,3,5-
triazaphosphaadamantane). The viability of the kidney slices after metallodrug treatment was evaluated by ATP content 
determination and histomorphology analysis. A concentration dependent decrease in viability of PCKS was observed after 
exposure to cisplatin or the Au(III) complex, which correlated with the increase in slice content of Pt and Au, respectively. 
Metal accumulation in kidney slices was analysed by ICP-MS. The involvement of OCTs and MATE transporters in the 
accumulation of both metal compounds in kidneys was evaluated co-incubating the tissues with cimitedine, inhibitor of OCT 
and MATE. Studies of mRNA expression of the markers KIM-1, villin, p53 and Bax showed that cisplatin damages proximal 
tubules, whereas the Au(III) complex preferentially affects the distal tubules. However, no effect of cimetidine on the toxicity 
or accumulation of cisplatin and the Au(III) complex was observed. The effect of temperature on metallodrug accumulation 
in kidneys suggests the involvement of a carrier-mediated uptake process, other than OCT2, for cisplatin; while carrier-
mediated excretion was suggested in the cases of the Au(III) complex.  
Introduction 
Cisplatin (cis-diamminedichloridoplatinum(II), Figure 1) is an 
antineoplastic drug used in the treatment of many solid 
tumours, including those of the head, neck, lung, and testis. 
Unfortunately, severe side effects following cisplatin treatment 
may occur, including ototoxicity and myelosuppression,1 with 
the main dose-limiting side effect being nephrotoxicity.2 The 
pathophysiological basis of cisplatin nephrotoxicity has been 
studied for the last four decades, and the emerging picture is 
that the exposure of tubular cells to cisplatin activates complex 
signalling pathways, leading to tubular cell injury and death via 
both apoptosis and necrosis.3 
Studies in rats and mice suggest that the drug undergoes 
metabolic activation in the kidney to a more potent toxin, a 
process possibly involving glutathione and mediated by 
gluthathione-S-transferase.4 Activation of cisplatin to its highly 
reactive and toxic metabolites includes spontaneous 
intracellular aquation reactions, which involve the substitution 
of the chlorido ligands with water/hydroxide molecules.5,6 
Previously reported studies using kidney slices,7 cultured renal 
epithelial cells8 and isolated perfused proximal tubule 
segments9 have provided evidence for basolateral carrier-
mediated uptake of cisplatin. Moreover, it was found that 
cisplatin concentration within the kidneys exceeds the 
concentration in blood by at least five-fold, suggesting 
accumulation of the drug by renal parenchymal cells.7 
At a molecular level, experimental evidence has led to the 
conclusion that cisplatin enters cells via two main pathways: (i) 
passive diffusion and (ii) facilitated uptake by a number of 
transport proteins,6,10 including copper transporters (CTR) and 
organic cation transporters (OCT).6,11 Pabla et al demonstrated 
that CTR1 is mainly expressed in both proximal and distal 
tubular cells in mouse kidneys, whereas cisplatin toxicity has 
been observed mainly in the proximal tubular cells.11 In the  
 
 
same study, it was shown that down-regulation of CTR1 in 
human embryonic kidney cells (HEK293), by small interfering 
RNA or copper (Cu(I)) pre-treatment, resulted in decreased 
cisplatin uptake.  
Various studies, demonstrating that cisplatin can be 
transported by OCTs in cells, are based on competition 
experiments with other established OCTs substrates such as 
tetraethylammonium (TEA) and inhibitors such as cimetidine.12–
14 OCTs belong to the solute carrier SLC22A family consisting of 
three sub-categories: the electrogenic transporter (OCT1-3), 
electroneutral organic cation/carnitine transporter (OCTN1-3) 
and the organic anion transporter (OATs and urate transporters, 
URAT-1).15 Many transporters of the SLC22A family are found in 
secretory organs such as the liver and the kidneys, as well as the 
intestine, where they play pivotal roles in drug adsorption and 
excretion.16 Moreover, different OCTs show species and tissue-
specific distribution. For example, the human OCT1 is highly 
expressed in the sinusoidal membrane of the liver and in the 
apical membrane of the jejunum17 but not in the kidney. 
Instead, human OCT2 is mainly expressed in the basolateral side 
of renal proximal tubule cells, and in the dopaminergic brain 
regions.18 In order to correctly interpret translational studies, it 
is important to note that in rodents, both OCT1 and OCT2 show 
a high renal expression in the basolateral membrane of 
proximal tubule cells. 19–21 hOCT3 shows a much broader tissue 
distribution, including skeletal muscle, heart, brain, and 
placenta, but the distribution in the membrane and 
physiological role of OCT3 are not yet clearly understood.16 The 
interaction of cisplatin with hOCT2 in the kidney, or hOCT1 in 
the liver, was investigated with the fluorescent cation 4-[4-
(dimethyl-amino)styril]-methylpyridinium (ASP) in stably 
transfected HEK293 cells overexpressing these transporters, 
and in cells physiologically expressing them, such as human 
 proximal tubules and human hepatocyte couplets.22 Notably, 
cisplatin inhibited ASP transport in hOCT2-HEK293 but not in 
hOCT1-HEK293. Furthermore, incubation with cisplatin induced 
apoptosis in hOCT2-HEK293 cells; a process that was completely 
suppressed by simultaneous incubation with the hOCT2 
inhibitor cimetidine. Moreover, in isolated human proximal 
tubules, cisplatin competed with basolateral organic cation 
transport, whereas it had no effect in human hepatocytes.22 
Overall, these findings support the idea of the interaction of 
cisplatin with hOCT2 in renal proximal tubules, but not with 
hOCT1, possibly explaining its organ-specific toxicity. 
In 2010, the functional effects of cisplatin treatment on 
kidney and hearing were studied in vivo in wild-type and OCT1/2 
double-knockout mice.23 No sign of ototoxicity and only mild 
nephrotoxicity were observed after cisplatin treatment of 
knockout mice, while cisplatin accumulation in the kidneys was 
reduced.23 Co-medication of wild-type mice with cisplatin and 
the organic cation cimetidine resulted in protection against 
ototoxicity and partly against nephrotoxicity.23 Moreover, 
experiments in rats showed that treatment with both cisplatin 
and cimetidine did not interfere with the antitumoral activity of 
the Pt drug.24 Based on these studies and others, hOCT2 has 
been proposed as a target for protective therapeutic 
interventions in cisplatin chemotherapy.  
Furthermore, membrane transporters are also involved in 
carrier-mediated Pt efflux pathways, including the ATP-binding 
cassette (ABC) multidrug transporters6,25 and the multidrug and 
toxin extrusion proteins (MATEs).26–28 MATEs belong to the 
SLC47 family and are also part of organic cation homeostasis. 
Specifically, MATEs act as H+/organic cation antiporters, 
transporting protons from the extracellular side to the 
cytoplasm in concomitance with organic cations export to the 
lumen of the proximal tubule. Two isoforms are known, 
SLC47A1 (MATE1) and SLC47A2 (MATE2-K). Both in human and 
in rat, MATE1 is primarily expressed in the liver and kidney, 
while MATE2-K exhibits a kidney-specific expression at the 
brush border membrane of the tubular cells. 29 Several studies 
have confirmed cisplatin transport by MATEs.13,14 Overall, these 
studies suggest that, in humans, the interplay between OCT2 
and MATE is responsible for the net renal secretion of cisplatin, 
and possibly also for the net accumulation of cisplatin in the 
tubular cells, but further investigation is essential to fully 
elucidate the complex pathways of cisplatin transport and 
related side-effects.30 
Within this framework, the lack of conclusive information is 
at least partly due to the lack of suitable models to study 
transport mechanisms in renal tissues. In vitro models, generally 
2D cell cultures, have been applied to study the mechanisms of 
action, metabolism and transport of metallodrugs.30 These 2D 
cultured cells usually are characterized by low level of 
differentiation and mostly consist of one cell type, thereby 
lacking interactions between the different cell types as in a 
tissue. Therefore, a model including all cell types in their natural 
environment is indispensable for studying complex, 
multicellular organ functions and the pharmacological and 
toxicological response to drugs, as well as for the identification 
of the transport mechanisms. The precision cut tissue slices 
(PCTS) is such a technique, where the original cell-cell and cell-
matrix contacts stay unaltered and as such is a useful technique 
for drug testing ex vivo.31 In a PCTS model, the tissue can remain 
viable during culture with physiological expression and 
localization of enzymes and transporters. Thus, the PCTS system 
is uniquely suited to examine molecular responses to toxicant 
exposures and compare species differences, and is nowadays a 
FDA-approved technology. 32 Recently, our group has 
successfully used the PCTS technique to study the toxic effects 
of experimental anticancer organometallic compounds,33–36 
aminoferrocene-containing pro-drugs,37 ruthenium-based 
kinase inhibitors,38 as well as supramolecular metallacages as 
possible drug delivery systems.39 
Interestingly, nephrotoxic side effects induced by cisplatin 
were already investigated in human and rat kidney slices and 
characterized morphologically, as well as in terms of gene 
expression and functional changes, providing evidence for the 
mechanisms of apoptosis induction.40–42 Furthermore, the 
acute nephrosis of tubular epithelium induced by cisplatin in 
vivo was reproduced in both human and rat kidney slices ex 
vivo, while the glomerulus appeared unaffected even at high 
drug concentration (80 µM).40  
However, further studies are necessary to evaluate possible 
transport mechanisms using the precision-cut kidney slices 
(PCKS) ex vivo model.  
Here, we report on the toxicity and mechanisms of 
accumulation and transport of cisplatin studied in rat kidney 
using the PCKS technique. Tissues viability was assessed by 
three different methods, including ATP content, 
histomorphology, and mRNA determination of different 
biomarkers. Moreover, intracellular metal accumulation was 
determined by inductively coupled plasma mass spectrometry 
(ICP-MS). In addition, the involvement of carrier–mediated 
transport was investigated performing experiments in the 
presence of cimetidine, an inhibitor of both rat OCTs and MATE 
transporters, as well as varying the temperature of tissues 
incubation. Furthermore, we also studied the toxicity, 
accumulation and transport mechanisms of another 
metallodrug, the previously reported experimental cytotoxic 
cyclometallated (C^N) Au(III) complex [Au(pyb-H)(PTA)Cl]PF6 
(PTA = 1,3,5-triazaphosphaadamantane, Figure 1) featuring a 
relatively stable Au(III) centre.43 Interestingly, this Au(III) 
complex showed promising antiproliferative effects against 
several cancer cell lines and inhibits the zinc-finger enzyme 
PARP-1 in nM concentrations.43 For most of these new 
generation experimental metal-based compounds with 
cytotoxicity towards cancer cells, the mechanisms leading to 
their pharmacological and toxicological profiles are still not fully 
elucidated and different biological targets and transport 
systems have been proposed which still need validation.30 
 
  
Figure 1. Structure of the anticancer metal complexes evaluated in this study. 
Experimental methods 
Materials 
Cisplatin and cimetidine were purchased from Sigma Aldrich, and the 
Au(III) complex was synthesized according to the protocol previously 
reported.43 
 
PCKS 
Male Wistar rats (Charles River, France) of 250-300 g were 
housed under a 12 h dark/light cycle at constant humidity and 
temperature. Animals were permitted ad libitum access to tap 
water and standard lab chow. All experiments were approved 
by the committee for care and use of laboratory animals of the 
University of Groningen and were performed according to strict 
governmental and international guidelines. 
Kidneys were harvested (from rats anesthetized with 
isoflurane) and immediately placed in University of Wisconsin 
solution (UW, ViaSpan, 4⁰C) until further use. After removing 
fat, kidneys were cut in half lengthwise using a scalpel, and 
cortex cores of 5 mm diameter were made from each half 
perpendicular to the cut surface using disposable Biopsy 
Punches (KAI medical, Japan). PCKS were made as described by 
de Graaf et al.31,44 The cores were sliced with a Krumdieck tissue 
slicer (Alabama R&D, Munford, AL, USA) in ice-cold Krebs-
Henseleit buffer, pH 7.4 saturated with carbogen (95% O2 and 
5% CO2). Kidney slices weighing about 3 mg (~150 μm 
thickness), were incubated individually in 12-well plates 
(Greiner bio-one GmbH, Frickenhausen, Austria), at 37°C in 
culture medium, Williams’ medium E (WME, Gibco by Life 
Technologies, UK) with glutamax-1, supplemented with 25 mM 
D-glucose (Gibco) and ciprofloxacin HCl (10 µg/mL, Sigma-
Aldrich, Steinheim, Germany) in an incubator (Panasonic 
biomedical) in an atmosphere of 80% O2 and 5% CO2 with 
shaking (90 times/min).  
In order to remove debris and dead cells before the start of 
the experiments, PCKS were pre-incubated for 1 h in culture 
medium and then transferred to new plates containing fresh 
medium. 
 
Evaluation of ATP content. After PCKS pre-incubation, different 
concentrations of cisplatin and Au(III) complex were added to the 
wells and the slices were incubated for 10 min, 30 min, 60 min or 24 
h. After the incubation time, slices were collected for ATP and protein 
determination, by snap freezing in 1 ml of ethanol (70% v/v) 
containing 2 mM EDTA with pH=10.9. After thawing, the slices were 
homogenized using a mini bead beater and centrifuged. The 
supernatant was used for the ATP essay and the pellet was dissolved 
in 5N NaOH for the protein essay. ATP was measured using the ATP 
Bioluminescence Assay kit CLS II (Roche, Mannheim, Germany) as 
described in the experimental section. The ATP content was 
corrected by the protein amount of each slice and expressed as 
pmol/μg protein. The protein content of the PCKS was determined 
by the Bio-Rad DC Protein Assay (Bio-Rad, Munich, Germany) using 
bovine serum albumin (BSA, Sigma-Aldrich, Steinheim, Germany) for 
the calibration curve.  
 
Evaluation of involvement of rOCT2/rMATE drug transporter. 
To evaluate the involvement of rOCT2 as uptake transporter 
and rMATE as efflux transporter, the slices were first incubated 
for 30 min with a non-toxic concentration of 100 µM cimetidine. 
Afterwards, cisplatin or the Au(III) complex were added in the 
selected concentrations. Each condition was evaluated in 
triplicates after 24 h incubation. Control slices were taken 
directly after slicing, after pre-incubation and after 24 h 
incubation. 
 
Histomorphology 
Kidney slices were fixated in 4% formalin for 24 h and stored in 
70% ethanol at 4⁰C until processing for morphology studies. 
After dehydration, the slices were embedded in paraffin and 4 
μm sections were made, which were mounted on glass slides 
and PAS staining was used for histopathological evaluation. 
Briefly, the glass slides were deparaffinised, washed with 
distilled water, followed by treatment with a 1% aqueous 
solution of periodic acid for 20 min and subsequently Schiff 
reagent for 20 min. Then, the slides were rinsed with tap water; 
finally, a counterstain with Mayer’s haematoxylin (5 min) was 
used to visualize the nuclei. 
Expression determination of kidney-injury molecule-1 (KIM-1), 
villin, p53 and Bax. 
RNA isolation. Three precision cut kidney slices from each 
treatment group were pooled and snap-frozen in RNase free 
Eppendorf tubes. RNA was isolated with the Maxwell® 16 
simplyRNA Tissue Kit (Promega, Leiden, the Netherlands). Slices 
were homogenised in homogenisation buffer using a minibead 
beater. The homogenate was diluted 1:1 with lysis buffer. The 
mixture was processed according to the manufacturer’s 
protocol using the Maxwell machine. RNA concentration was 
quantified on a NanoDrop One UV-Vis Spectrophotometer 
(Thermoscientific, Wilmington, US) right before conversion to 
cDNA. 
 
cDNA generation. RNA samples were diluted 0.5 μg in 8.5 μl of 
RNAsa free water. cDNA was generated from RNA using random 
primers with TaqMan Reverse Transcription Reagents Kits 
(Applied Biosystems, Foster City, CA). To each sample the 
following solutions were added: 2.5 μL 5x RT-buffer, 0.25 μL 
 10mM dNTP’s, 0.25 μL Rnasin (10 units), 0.5 μL M-MLV Reverse 
Transcriptase (100 units), 0.5 μL random primers. 
qPCR. Real-time quantitative PCR was used to determine 
relative mRNA levels of KIM-1, villin, p53 and Bax. PCR was 
performed using SensiMixTM SYBR Low-ROX kit (Bioline, 
London, UK) with the QuantStudio 7 Flex Real-Time PCR System 
(Thermoscientific, Wilmington, US) with 1 cycle of 10 min at 
95°C, 40 cycles of 15 sec at 95°C and 25 sec at 60°C, with a final 
dissociation stage of 15 sec at 95°C, 1 min at 60°C and 15 sec at 
95°C. cDNA for each sample was diluted to 10 ng/μl and 
measured in triplicate. All primers were purchased from Sigma-
Aldrich. Fold induction of each gene was calculated using the 
housekeeping gene GAPDH. 
 
The primer sequences used in qPCR were: 
KIM-1: 5′-GTGAGTGGACAAGGCACAC-3′ (forward), and  
5′-AATCCCTTGATCCATTGTTT-3′ (reverse);  
villin: 5′- GCTCTTTGAGTGCTCCAACC-3′ (forward), and  
5′-GGGGTGGGTCTTGAGGTATT′ (reverse);  
p53: 5′- CCCCTGAAGACTGGATAAC-3′ (forward), and  
5′-AACTCTGCAACATCCTGGGG-3′ (reverse);  
Bax: 5′- ACAGGGGCCTTTTTGTTACAG-3′ (forward), and  
5′-GGGGAGTCCGTGTCCACGTCA-3′ (reverse);  
GAPHD: 5’-CGCTGGTGCTGAGTATGTCG-3’ (forward) and  
5’-CTGTGGTCATGAGCCCTTCC-3’ (reverse).  
 
 
ICP-MS analysis 
After incubation with different concentrations of cisplatin or the 
Au(III) compound, PCKS were washed with ice-cold Krebs-
Henseleit buffer and snap-frozen and stored at -80°C until the 
analysis. 
 
Sample preparation. The tissue samples were digested with 
100 µL nitric acid overnight, all samples were completely 
dissolved. 100 µL hydrochloric acid and 800 µL milliQ were 
added to produce a volume of 1 mL. Prior to analysis the 
samples were diluted 20 times with 0.65% HNO3/0.1% HCl. 
 
Pt and Au determination. The Pt and Au contents were 
quantitated applying a Perkin Elmer (Waltham, MA, USA) Sciex 
Elan DRC-e ICP-MS instrument, equipped with a Cetac ASX-
110FR autosampler, a 0.2 mL min-1 MicroMist U-series 
pneumatic concentric nebulizer (Glass Expansion, West 
Melbourne Vic, Australia) and a PC3 cyclonic spray chamber 
(Elemental Scientific Inc., Omaha, NE, USA). ICP-MS RF power, 
lens voltage and nebulizer gas and flow were optimized on a 
daily basis and other settings were: 1 sweep/reading, 25 
readings/replicate, 5 replicates, 50 ms dwell time. The 197Au+, 
195Pt+, and 194Pt+ isotopes were monitored. Pt and Au 
concentrations were determined by external calibration (0-20 
ppb Pt and Au). LODs were 0.1 and 0.2 µg L-1 for Pt and Au, (3*SD 
on blank, n=10) and the spike recovery were 102% and 99% for 
Pt and Au (n = 3), respectively. Pt and Au single element 
PlasmaCAL standards (SCP Science, Quebéc, Canada) were used 
and the standards were prepared in a mixture of 0.1% HCl and 
0.65% subboiled HNO3 in MilliQ water. This mixture was 
furthermore used to dilute samples after digestion and as blank 
solution. 
 
Temperature dependency. For the evaluation of temperature 
dependency, after the pre-incubation at 37°C for 1 h, rat kidney 
slices were incubated for 10, 30 and 60 min with the metal 
complexes at 37°C or 4°C, and were subsequently washed with 
ice-cold Krebs-Henseleit buffer and snap-frozen as described 
above. 
 
Statistics 
A minimum of three independent experiments were performed 
using slices in triplicates from each rat kidney. The TC50 values 
were calculated as the concentration reducing the viability of 
the slices by 50%, relative to the untreated samples using a 
nonlinear fitting of log(concentration compound) vs response 
and is presented as a mean (± SD) of at least three independent 
experiments. Statistical testing was performed with repeated 
measures ANOVA and Bonferroni as post hoc test to compare 
the treated samples with the untreated controls. A p-value of ≤ 
0.05 was considered to be significant. In all graphs and tables, 
the mean values and standard deviation (SD) are shown. 
Results and discussion 
Toxicity evaluation 
ATP content determination. Initially, to determine the toxicity of 
the evaluated compounds, PCKS were incubated with different 
concentrations of cisplatin and Au(III) complex for 24 h. In 
addition, another set of kidney slices of the same rat were co-
incubated with 100 µM cimetidine to assess its effect on the 
toxicity of cisplatin and Au(III) complex in the PCKS. It is 
hypothesized that this inhibitor for OCTs and MATE transporters 
might reduce the accumulation of cisplatin and thereby protects 
against toxicity. The viability of the kidney slices was determined 
by measuring the ATP/protein content. The obtained results are 
presented in Figure 2. Both compounds show concentration-
dependent reduction of viability. The Au(III) complex showed a 
higher toxicity than cisplatin, with TC50 values of 4.3 ± 0.2 µM 
and 17 ± 2.0 µM, respectively (Table 1). Co-incubation of 
cisplatin or Au(III) complex with 100 µM cimetidine did not 
result in any significant change of toxicity in the rat kidney slices. 
These results are in contrast with previously reported studies in 
in vitro cellular models. 22,23 It should be noted that cimetidine 
inhibits not only the uptake transporter OCT2, which is 
supposed to reduce cellular accumulation, but also the active 
efflux transporter MATE, which may result in higher 
accumulation in the slices and thereby increasing toxicity.45 
Thus, our toxicity evaluation results suggest that cisplatin and 
Au(III) complex accumulation is not dependent on rat OCTs or 
MATEs. 
 
Table 1. TC50 values for PCKS treated with cisplatin or Au(III) complex, in the 
absence and presence of cimetidine, for 24 h. 
 Compound 
TC50 
No cimetidine 
+ 100 µM 
cimetidine 
cisplatin 17.0 ± 2.0 14.7 ± 3.5 
Au(III) 
complex 
4.3 ± 0.2 4.4 ± 0.9 
 
 
Figure 2. Viability of PCKS treated for 24 h with different concentrations of 
cisplatin (top) and of Au(III) complex (bottom), without cimetidine (black bars) 
and co-incubated with cimetidine (grey bars, indicated as: + CIM). The error 
bars show the standard deviation of at least three independent experiments. 
 
 
Histomorphology 
The differential effects of cisplatin and Au(III) complex on PCKS 
viability, in the absence or presence of cimetidine, were further 
assessed by histomorphology. Specifically, Periodic Acid-Schiff 
staining (PAS) was used to evaluate slice integrity and 
particularly to visualize the basal membranes and epithelial 
brush border in the proximal tubule. After 24 h incubation, the 
untreated kidney slices show minor morphological changes, 
indicated by occasional pyknosis and swelling of tubular cells 
(Figure 3A). The kidney slices co-incubated with cimetidine (100 
µM) showed similar characteristics of integrity as the untreated 
controls (Figure 3A and 3B). However, the cell swelling is more 
evident in the samples treated with cimetidine, including slight 
Bowman’s space dilatation (Figure 3B).  
As expected, exposure of PCKS to cisplatin (Figure 3) and to 
the Au(III) complex (Figure 4) results in damage in several of the 
cellular structures in the cortex. In the case of cisplatin, at 5 µM 
concentration (Figure 3C-D) there is evidence of damage on the 
distal and proximal tubular cells as well as some dilatation of the 
Bowman’s space in the glomerulus, which seems more 
prominent in the samples treated with cimetidine. With the 
increase of the concentration of cisplatin to 10 and 25 µM 
(Figure 3E-H) the damage intensifies and disruption of the brush 
borders of the proximal tubules becomes more evident. 
Furthermore, cimetidine treatment did not reduce the kidney 
damage induced by cisplatin, and slices resulted to be equally 
affected by the metallodrug as those incubated without 
cimetidine.  
The tubular damage found in our study for cisplatin is in line 
with the results of Vickers et al. in rat PCKS. 40 However, in our 
study we observed that cisplatin also affects the glomerulus 
structure. This difference in toxicity profiles might be caused by 
the different culture media used, especially the presence of 
serum in the study of Vickers might be the cause of the 
difference between these results. In conclusion, our data shows 
tubular damage by cisplatin, which is not influenced by 
cimetidine, in line with the ATP viability data. 
 
For the samples exposed to the Au(III) complex, the increase in 
drug concentration does not produce any major differences 
with respect to the lower tested concentration. In fact, in all 
cases, extensive damage is observed mainly in the distal tubular 
cells, with the structure of the brush border in the proximal 
tubule almost intact (Figure 4 C-H). No difference was observed 
in the absence (Fig. 4, left column) or presence (Fig. 4, right 
column) of cimetidine. 
While cisplatin generates more damage towards the 
glomeruli and the proximal tubular cells, the Au(III) complex 
displayed selective damage of the distal tubular cells, which was 
also previously described for anticancer Au(I) complexes.36 
Overall, the presented histomorphology and ATP results 
show that there is no evidence of reduced toxicity in the slices 
exposed to either cisplatin or Au(III) complex co-incubated with 
cimetidine (Figures 3 and 4, right columns).  
 
 
 Figure 3. Morphology of rat precision cut kidney slices exposed to different 
concentrations of cisplatin for 24 h. Left column: absence of cimetidine; right 
column: co-incubation with cimetidine. A and B: 24 h control incubation; C 
and D: 5 µM; D and E: 10 µM; F and G: 25 µM h. PT: proximal tubule, DT: distal 
tubule, G: glomerulus, BSD: Bowman’s space dilatation, N: Necrotic areas. 
Scale bar indicates 50 µm. 
 
Figure 4. Morphology of rat precision kidney slices exposed to different 
concentrations of Au(III) complex for 24 h. Left column: absence of 
cimetidine; right column: co-incubation with cimetidine. A and B: 24 h control 
incubation; C and D: 1 µM; E and F: 2.5 µM; G and H: 5 µM. PT: proximal 
tubule, DT: distal tubule, G: glomerulus, BSD: Bowman’s space dilatation, N: 
Necrotic areas. Scale bar indicates 50 µm. 
Expression of kidney-injury molecule-1 (KIM-1), villin, p53 and Bax. 
The variation of the expression levels of different markers were 
evaluated in PCKS after incubation with the Pt(II) and the Au(III) 
metallodrugs. Specifically, kidney injury molecule-1 (KIM-1) and 
villin were chosen as proximal tubule damage specific 
biomarkers. An increase of KIM-1 fold expression is expected in 
the presence of tubular damage, 46,47 whereas decrease in the 
expression levels of villin is considered a sign of brush border 
damage.48–50 Additionally, p53 and Bax were studied to 
determine the role of apoptosis in the toxicity of PCKS upon 
exposure to cisplatin and to the Au(III) complex. In fact, it has 
been proposed that cisplatin induced nephrotoxicity consists of 
activation of multiple stress pathways, including p53 mediated 
responses and intrinsic and extrinsic apoptosis pathways (with 
Bax playing an important role in the intrinsic ones).51–54 Thus, 
KIM-1, villin, p53 and Bax mRNA expression was evaluated in 
PCKS after 3 h, 5 h and 24 h exposure with cisplatin and Au(III) 
complex at concentrations close to their TC25 and TC50. The 
obtained results are shown in Figure 5.  
 In the untreated control samples, the KIM-1 expression 
showed a tendency to increase over time compared with the 0 
h controls reaching a peak after 24 h, ca. 100-fold increase, 
(Figure 5A); these results suggest the tubular cells are per se 
undergoing damage by the slicing and/or culturing process. 
Interestingly, KIM-1 expression decreased with increasing 
cisplatin concentration compared to the time-matched 
controls; even the lowest concentration of cisplatin and the 
shortest period of incubation (7.5 μM – 3 h) resulted in a 
decreased KIM-1 expression compared to untreated controls. 
However, due to the high variation, this decrease reached 
significance only after 24 h exposure to 15 µM cisplatin. 
Interestingly, upon exposure to the Au(III) complex, no change 
in KIM-1 expression was observed. From these findings, it can 
be hypothesized that when slices are exposed to high 
concentrations of cisplatin, the cellular machinery of the 
proximal tubular cells is too damaged to be able to produce 
KIM-1 mRNA.  
As shown by the morphological studies, the gold compound 
seems to target more specifically the distal tubular cells, with 
reduced damage to the proximal tubular cells, explaining the 
lack of effect on KIM-1. Concerning villin mRNA expression 
(Figure 5B), a reduction up to 40% was observed in the controls 
after incubation for 24 h, indicating some damage of the brush 
border of the proximal tubular cells. However, no dose-
dependent effect of cisplatin was observed, while the Au(III) 
compound slightly reduced the villin expression, which only 
reached significance after 5 h at 2 µM.  
The assessment of the expression patterns of p53 (Figure 
5C) displayed a slight, but not significant increase of the p53 
expression during incubation of the control slices. Conversely, 
upon treatment with cisplatin after 5 h at 15 µM, a decrease of 
p53 expression is observed, as well as 24 h at 7.5 and 15 µM 
compared to the untreated samples at each time point. These 
results differ from the findings in the previously mentioned 
study of Vickers et al,40 where the expression of p53 increased 
in rat PCKS after treatment with cisplatin at 20 and 40 µM for 
24 and 48 h, respectively.40 Exposure to the Au(III) complex had 
no effect on p53 expression (Figure 5C, right panel).  
Finally, no significant difference in Bax expression levels was 
observed during incubation of the control samples (Figure 5D). 
Bax expression increased slightly but significantly after 24 h 
exposure to the highest concentration of both compounds. 
These results indicate possible activation of the intrinsic 
apoptotic pathway depending mainly on the mitochondrial 
integrity. This finding is in line with previous reports that 
indicate the possibility of induction of apoptosis independent of 
p53 after treatment with cisplatin of human and mouse cancer 
cell lines.54–59 
 
  
Figure 5. Fold change of KIM-1 (A), villin (B) p53 (C) and Bax (D) after exposure 
to cisplatin (left) and to the Au(III) complex (right) during 3 h, 5 h and 24 h. 
The untreated control (0 h) was set as 1 to calculate the relative fold induction 
(not shown). The error bars show the standard deviation of at least three 
independent experiments. Statistical significance was determined by 
repeated measures ANOVA and Bonferroni as post hoc test to compare the 
treated samples with the untreated controls for each time point (*: p<0.05, 
**: p<0.01, ***: p<0.001). 
Uptake studies 
Metal content determination by ICP-MS. In order to assess the 
intracellular accumulation of the tested compounds and to 
evaluate the relation between toxicity and intracellular metal 
content, we determined the Pt and Au content of PCKS exposed 
to cisplatin and to the Au(III) complex by ICP-MS. Thus, PCKS 
were incubated for 24 h in the same conditions as for the ATP 
determination. The concentrations of cisplatin and Au(III) 
complex used were below or around their TC50. As can be seen 
in Figure 6, the Pt and Au contents increase as a function of the 
compounds’ initial concentration (up to 110.3 ng Pt per slice in 
the case of slices treated with 10 M cisplatin, and up to 84 ng 
Au per slice treated with 5 M of Au(III) complex). However, the 
obtained results did not show a significant difference between 
the samples treated with cimetidine or without it, which is in 
line with the viability and histomorphology studies above, 
suggesting that OCT and MATE are not involved in the transport 
of the compounds at the tested concentrations. Moreover, it is 
worth mentioning that the Au(III) complex appears to be more 
efficiently accumulated into PCKS than cisplatin: the amount of 
Au and Pt after 24 h of incubation is approximately the same 
(~28 ng) for the samples treated with cisplatin at 3 µM 
concentration or Au(III) complex at 1 µM. Additionally, from the 
obtained results, it can be calculated that the accumulation of 
cisplatin and of the Au(III) complex results in approximately 20-
fold and 30-fold increased concentration of the metals in the 
slices compared to the medium, respectively. This is in line with 
the reported accumulation of cisplatin in kidneys in vivo,40 
indicating either high binding or metabolism in the cells, or the 
involvement of active uptake transporters.  
 
Figure 6. Total metal content determined by ICP-MS in PCKS treated with 
cisplatin or with the Au(III) complex at different concentrations, without and 
with cimetidine (indicated as: + CIM), for 24 h. The error bars show the 
standard deviation of at least three independent experiments. 
 
Effect of temperature on uptake in PCKS. To evaluate if the 
uptake of cisplatin and of the Au(III) complex is by passive 
diffusion or carrier-mediated transport, PCKS were incubated 
with the selected compounds at three different concentrations 
at 4°C or 37 °C over a period of 60 min. Slices were collected 
after 0, 10, 30 and 60 min incubation with the metallodrugs, 
washed with ice-cold Krebs Henseleit buffer and their metal 
content was evaluated by ICP-MS to assess the effect of 
different temperatures on the uptake of the drugs.  
 Slices treated with cisplatin at 5 µM and 25 µM incubated at 
4°C or 37°C showed an initial rapid uptake phase followed by a 
slower accumulation, indicating sequestration by excretion. No 
significant differences in the Pt content were seen between the 
two temperatures (Figure 7), suggesting that only passive 
uptake mechanisms play a role at these tested concentrations. 
However, slices treated with cisplatin at 100 µM showed 
significant differences at 30 and 60 min, with a lower Pt content 
in the slices incubated at 4°C compared to 37°C, indicating that 
carrier-mediated uptake mechanisms are implicated in cisplatin 
accumulation in cells at this high concentration. Apparently, 
both passive and carrier-mediated mechanisms are involved 
with cisplatin uptake at low concentrations, while carrier-
mediated transport is only significantly involved in Pt 
accumulation at higher concentrations, indicating a low affinity 
for the transporter.6,26,30 
 
 Figure 7. Pt content (ng per slice) in PCKS treated with cisplatin at 5 µM, 25 
µM, 100 µM. Incubated at 37°C and 4°C and collected at three different time 
points (10, 30 and 60 min). t=0 value for the lowest concentration was not 
determined due to limitations in the amount of tissue, but is estimated to be 
0.8 ng Pt/slice based on the values found for the two higher concentrations. 
The error bars show the standard deviation of at least three independent 
experiments. 
Remarkably, evaluation of the Au content in rat kidney slices  
upon treatment with the Au(III) complex showed a significant 
higher Au accumulation at 4°C compared to 37°C at all 
concentrations and time points (Figure 8). A fast initial uptake 
rate is followed by a slower uptake rate, which is observed for 
all concentrations during 60 min. The higher Au content found 
in the slices incubated at 4°C could be due to the inhibition of 
active excretion mechanisms such as an efflux transporter, 
other than MATE, at this low temperature. 
 
Figure 8. Au content (ng per slice) in PCKS treated with 1 at 2 µM (A), 5 µM 
(B), 10 µM (C). Incubated at 37°C and 4°C and collected at three different time 
points (10, 30 and 60 minutes). t=0 value for the lowest concentration was 
not determined due to limitations in the amount of tissue, but is estimated to 
be 0.5 ng Au/slice. The error bars show the standard deviation of at least 
three independent experiments. 
Conclusions 
In the past decades, several studies have been carried out to 
elucidate the mechanisms of uptake and efflux of cisplatin on 
kidney cells, related to the nephrotoxic effects of this 
extensively used anticancer drug, and various in vitro assays 
were conducted. Nonetheless, such transport mechanisms are 
not yet fully understood.30 Moreover, the mechanisms leading 
to toxicity and accumulation of new generation anticancer gold 
complexes have not been fully elucidated. Even less is known on 
the transport of organometallic gold complexes in the kidney. 
Therefore, we investigated and compared the toxicity and 
the accumulation of cisplatin and a cytotoxic experimental 
organometallic Au(III) complex in rat kidney tissues using the 
PCKS technology. Additionally, we evaluated the involvement of 
rOCTs and rMATE transporters using their inhibitor cimetidine, 
in competition experiments. Furthermore, passive or active 
transport mechanisms were assessed by measuring metal 
uptake by ICP-MS in PCKS at 37°C or 4°C, respectively.  
As expected, a concentration dependent decrease in viability of 
PCKS was observed after 24 h exposure to both compounds, 
which correlated with the increase in PCKS content of platinum 
and gold after treatment. The gold complex seems to be more 
toxic for the kidney slices than cisplatin based on the TC50’s 
being 4.3 ± 0.2 µM and 17 ± 2.0 µM respectively. Interestingly, 
the histomorphological changes after treatment suggest that 
the Au(III) compound exerts its toxicity towards different target 
cells than cisplatin, showing extensive damage of the distal 
tubular cells, whereas cisplatin is more toxic towards the 
proximal tubular cells. The latter results are in line with 
previously reported studies.36,40 However, at variance with 
other studies present in the literature using cell cultures or 
isolated human tubuli,22–24 in our ex vivo model no effect of co-
incubation with cimetidine on the toxicity or accumulation of 
cisplatin and Au(III) complex was found. Based on these results 
we conclude that rOCTs and rMATE transporters do not play a 
prominent role in cisplatin or Au(III) complex accumulation in 
the rat kidney slices at the tested cimetidine concentration. 
Alternatively, cimetidine may inhibit MATE transporters with 
higher efficacy than OCT, thereby reducing its renoprotective 
effect. 
Furthermore, KIM-1 and villin mRNA expression were 
studied as markers of proximal tubular damage. KIM-1 
expression decreased with increasing cisplatin concentrations, 
whereas the Au(III) complex induced no change in KIM-1 
expression at increasing concentrations. These findings are in 
agreement with the different localization of the damage in the 
tissue. In contrast, villin expression was not affected by 
cisplatin, but was slightly reduced by the Au(III) complex. It 
could be important to evaluate other markers of damage 
including markers of structures other than proximal tubular 
cells to assess kidney injury induced by metallodrugs in a more 
comprehensive way. Surprisingly, p53 overexpression was not 
induced in PCKS exposed to cisplatin as previously reported.40 
However, as mentioned before, the culture conditions, and 
specifically the serum protein content of the medium, and the 
concentrations of cisplatin used were different and these 
circumstances can lead to substantial differences in the 
obtained results. Moreover, Bax mRNA expression increased 
over time in control slices indicating possible activation of 
intrinsic apoptotic pathways. Nevertheless, the increment is 
higher when PCKS were treated during 24 h with the highest 
concentration of cisplatin or gold compound as evidence of 
further stress compared to the controls.  
 To get insight into the specific toxic mechanisms activated 
after treatment with cisplatin or other metallodrugs, it is 
imperative to consider the species and tissue distinct gene 
expression profiles during incubation without and with drugs. 
Specifically, cisplatin is known to activate several stress 
pathways, but it is dependent on the concentration, cell type 
and culture conditions whether the cells die by apoptosis, 
necrosis or both.  
Our ex vivo studies to evaluate the passive or active 
character of the transport of cisplatin and the Au(III) complex 
revealed that both passive and active processes might play a 
role. Moreover, the uptake of cisplatin is achieved by both 
passive and active mechanisms but this becomes evident only 
at higher concentrations, indicating a low affinity for the active 
transporters. On the other hand, the results obtained for the 
Au(III) complex suggested an important role of carrier-mediated 
excretion, shown by the increased Au content in the slices 
incubated at 4°C compared to 37°C. 
Further studies to explore the role of different transporters 
are needed to better understand the concentration dependent 
and organ-specific toxicity of our metallodrugs, which is 
valuable to design new experimental metallodrugs with 
reduced side effects in specific tissues. Certainly, the use of 
PCKS offers good opportunities to evaluate toxicity, uptake and 
 accumulation of metallodrugs in different organs and species, 
and finally to get insight into the effect in human tissues derived 
from patients. However, optimization of the experimental set-
up to reduce the damage of the PCKS induced by culturing is still 
necessary to exclude possible interference on the obtained 
results.  
Furthermore, new advanced approaches, such as the 
CRISPR-Cas9 genome editing, should be applied to validate both 
transport and intracellular trafficking mechanisms for 
metallodrugs. This technology has been recently applied to 
individually knock out the human copper transporters CTR1 and 
CTR2 and the copper chaperones ATOX1 and CCS in cells, in 
vitro.60 The obtained results suggest that these proteins are not 
essential for the mechanism by which cisplatin enters human 
embryonic kidney cells (HEK293T) and ovarian carcinoma 
OVCAR8 cell lines and is transported to the nucleus, 
contradicting numerous previously reported studies in the field. 
Overall, new investigational efforts should be spent to elucidate 
the complex mechanism of toxicity of metallodrugs and the role 
of different transport pathways in tissues. 
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